Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)

NCT04564027 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04564027
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04564027 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
December 1, 2020
Completion date
February 18, 2025
Enrollment
54 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumours